Study identifier:NIS-CGE-ATA-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Compliance of patients with essential hypertension treated with Candesartan or Candesartan/hydrochlorothiazide
essential hypertension
-
No
-
Unmapped
1773
Observational
None - None
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2008 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.
No locations available
Arms | Assigned Interventions |
---|---|
1 Patient with essential hypertension under treatment with candesartan or candesartan HCT | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.